Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2018 (2018), Article ID 8031328, 11 pages
https://doi.org/10.1155/2018/8031328
Research Article

Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma

1Department of Abdominal Surgery, Military Medical Academy, Belgrade, Serbia
2Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
3Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
4Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
5Institute for Medical Research, Military Medical Academy, Belgrade, Serbia
6Department of Surgery, Faculty of Medicine Foca, University of East Sarajevo, Sarajevo, Bosnia and Herzegovina

Correspondence should be addressed to Nevena Gajovic; moc.oohay@anevencivojag

Received 29 December 2017; Revised 26 February 2018; Accepted 5 March 2018; Published 4 April 2018

Academic Editor: Amedeo Amedei

Copyright © 2018 Milan Jovanovic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Arnold, M. S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, “Global patterns and trends in colorectal cancer incidence and mortality,” Gut, vol. 66, no. 4, pp. 683–691, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Ponz de Leon, G. Rossi, C. di Gregorio et al., “Epidemiology of colorectal cancer: the 21-year experience of a specialised registry,” Internal and Emergency Medicine, vol. 2, no. 4, pp. 269–279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. A. R. Marley and H. Nan, “Epidemiology of colorectal cancer,” International Journal of Molecular Epidemiology and Genetics, vol. 7, no. 3, pp. 105–114, 2016. View at Google Scholar
  5. C. M. Johnson, C. Wei, J. E. Ensor et al., “Meta-analyses of colorectal cancer risk factors,” Cancer Causes & Control, vol. 24, no. 6, pp. 1207–1222, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. E. S. Roth, D. T. Fetzer, B. J. Barron, U. A. Joseph, I. W. Gayed, and D. Q. Wan, “Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression,” BMC Cancer, vol. 9, no. 1, p. 274, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Wiegering, J. Riegel, J. Wagner et al., “The impact of pulmonary metastasectomy in patients with previously resected colorectal cancer liver metastases,” PLoS One, vol. 12, no. 3, article e0173933, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. J. N. Primrose, “Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation,” Gut, vol. 50, no. 1, pp. 1–5, 2002. View at Publisher · View at Google Scholar
  9. T. Veen, K. Stormark, B. S. Nedrebø et al., “Long-term follow-up and survivorship after completing systematic surveillance in stage I-III colorectal cancer: who is still at risk?” Journal of Gastrointestinal Cancer, vol. 46, no. 3, pp. 259–266, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. T. M. Geiger and R. Ricciardi, “Screening options and recommendations for colorectal cancer,” Clinics in Colon and Rectal Surgery, vol. 22, no. 4, pp. 209–217, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Zdravkovic, M. Pavlovic, G. Radosavljevic, and I. Jovanovic, “Serum levels of immunosuppressive cytokines and tumor markers in metastatic colorectal carcinoma,” Journal of BUON, vol. 22, pp. 1–8, 2017. View at Google Scholar
  12. N. D. Zdravkovic, I. P. Jovanovic, G. D. Radosavljevic et al., “Potential dual immunomodulatory role of VEGF in ulcerative colitis and colorectal carcinoma,” International Journal of Medical Sciences, vol. 11, no. 9, pp. 936–947, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. K. L. Wu, H. H. Chen, C. T. Pen et al., “Circulating galectin-1 and 90K/mac-2BP correlated with the tumor stages of patients with colorectal cancer,” BioMed Research International, vol. 2015, Article ID 306964, 7 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Wagner, C. G. Peterson, P. Ridefelt, P. Sangfelt, and M. Carlson, “Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 36, pp. 5584–5589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Tibble, G. Sigthorsson, S. Bridger, M. K. Fagerhol, and I. Bjarnason, “Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease,” Gastroenterology, vol. 119, no. 1, pp. 15–22, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Tibble, K. Teahon, B. Thjodleifsson et al., “A simple method for assessing intestinal inflammation in Crohn’s disease,” Gut, vol. 47, no. 4, pp. 506–513, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Larsen, H. Y. Chen, J. Saegusa, and F. T. Liu, “Galectin-3 and the skin,” Journal of Dermatological Science, vol. 64, no. 2, pp. 85–91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Y. Chen, F. T. Liu, and R. Y. Yang, “Roles of galectin-3 in immune responses,” Archivum Immunologiae et Therapiae Experimentalis, vol. 53, no. 6, pp. 497–504, 2005. View at Google Scholar
  19. V. Desmedt, S. Desmedt, J. R. Delanghe, R. Speeckaert, and M. M. Speeckaert, “Galectin-3 in renal pathology: more than just an innocent bystander,” American Journal of Nephrology, vol. 43, no. 5, pp. 305–317, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Lukic, N. Gajovic, I. Jovanovic et al., “Potential hepatoprotective role of galectin-3 during HCV infection in end-stage renal disease patients,” Disease Markers, vol. 2017, Article ID 6275987, 8 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Endo, S. Kohnoe, E. Tsujita et al., “Galectin-3 expression is a potent prognostic marker in colorectal cancer,” Anticancer Research, vol. 25, no. 4, pp. 3117–3121, 2005. View at Google Scholar
  22. K. L. Wu, E. Y. Huang, W. L. Yeh, C. C. Hsiao, and C. M. Kuo, “Synergistic interaction between galectin-3 and carcinoembryonic antigen promotes colorectal cancer metastasis,” Oncotarget, vol. 8, no. 37, pp. 61935–61943, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Dignass, R. Eliakim, F. Magro et al., “Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis,” Journal of Crohn’s and Colitis, vol. 6, no. 10, pp. 965–990, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Gomollón, S. García-López, B. Sicilia, J. P. Gisbert, J. Hinojosa, and Grupo Espa˜nol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa, “Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU,” Gastroenterología y Hepatología, vol. 36, no. 2, pp. 104–114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Rutgeerts, W. J. Sandborn, B. G. Feagan et al., “Infliximab for induction and maintenance therapy for ulcerative colitis,” The New England Journal of Medicine, vol. 353, no. 23, pp. 2462–2476, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. G. D’Haens, W. J. Sandborn, B. G. Feagan et al., “A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis,” Gastroenterology, vol. 132, no. 2, pp. 763–786, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Geboes, R. Riddell, A. Ost, B. Jensfelt, T. Persson, and R. Löfberg, “A reproducible grading scale for histological assessment of inflammation in ulcerative colitis,” Gut, vol. 47, no. 3, pp. 404–409, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. R. M. Heilmann, S. M. Cranford, A. Ambrus et al., “Validation of an enzyme-linked immunosorbent assay (ELISA) for the measurement of canine S100A12,” Veterinary Clinical Pathology, vol. 45, no. 1, pp. 135–147, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Prakash, P. Stumbles, and C. Mansfield, “Initial validation of cytokine measurement by ELISA in canine feces,” Open Journal of Veterinary Medicine, vol. 03, no. 6, pp. 282–288, 2013. View at Publisher · View at Google Scholar
  30. M. Jovanovic, N. Zdravkovic, I. Jovanovic et al., “TGF-β as a marker of ulcerative colitis and disease severity,” Serbian Journal of Experimental and Clinical Research, 2018. View at Publisher · View at Google Scholar
  31. American Joint Committee on Cancer, AJCC Cancer Staging Manual, Springer, New York, NY, USA, 7th edition, 2010. View at Publisher · View at Google Scholar
  32. Q. Yang, I. Mori, T. Sakurai et al., “Correlation between nuclear grade and biological prognostic variables in invasive breast cancer,” Breast Cancer, vol. 8, no. 2, pp. 105–110, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. S. R. Hamilton and L. A. Aaltonen, “Pathology and genetics: tumours of the digestive system,” in World Health Organization Classification of Tumours, S. R. Hamilton and L. A. Aaltonen, Eds., pp. 103–143, IARC, Lyon, France, 3rd edition, 2000. View at Google Scholar
  34. G. Lanzaa, L. Messerini, R. Gafа, and M. Risio, “Colorectal tumors: the histology report,” Digestive and Liver Disease, vol. 43, pp. S344–S355, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Formica, V. Cereda, A. Nardecchia, M. Tesauro, and M. Roselli, “Immune reaction and colorectal cancer: friends or foes?” World Journal of Gastroenterology, vol. 20, no. 35, pp. 12407–12419, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Johansson, D. G. Denardo, and L. M. Coussens, “Polarized immune responses differentially regulate cancer development,” Immunological Reviews, vol. 222, no. 1, pp. 145–154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Klampfer, “Cytokines, inflammation and colon cancer,” Current Cancer Drug Targets, vol. 11, no. 4, pp. 451–464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Pernot, M. Terme, T. Voron et al., “Colorectal cancer and immunity: what we know and perspectives,” World Journal of Gastroenterology, vol. 20, no. 14, pp. 3738–3750, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Kitajima, T. Ito, D. J. Tumes et al., “Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells,” Cancer Research, vol. 71, no. 14, pp. 4790–4798, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Kanazawa, K. Yoshihara, H. Abe et al., “Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients,” Anticancer Research, vol. 25, no. 1B, pp. 443–449, 2005. View at Google Scholar
  41. A. Agarwal, S. Verma, U. Burra, N. S. Murthy, N. K. Mohanty, and S. Saxena, “Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder,” Cancer Immunology, Immunotherapy, vol. 55, no. 6, pp. 734–743, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Abtahi, F. Davani, Z. Mojtahedi, S. V. Hosseini, A. Bananzadeh, and A. Ghaderi, “Dual association of serum interleukin-10 levels with colorectal cancer,” Journal of Cancer Research and Therapeutics, vol. 13, no. 2, pp. 252–256, 2017. View at Publisher · View at Google Scholar · View at Scopus
  43. K. D. Johnson, O. V. Glinskii, V. V. Mossine et al., “Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia,” Neoplasia, vol. 9, no. 8, pp. 662–670, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Nangia-Makker, V. Balan, and A. Raz, “Regulation of tumor progression by extracellular galectin-3,” Cancer Microenvironment, vol. 1, no. 1, pp. 43–51, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Tao, L. Jin, L. Dechun, Y. Hongqiang, K. Changhua, and L. Guijun, “Galectin-3 expression in colorectal Cancer and Its correlation with clinical pathological characteristics and prognosis,” Open Mededicine, vol. 12, pp. 226–230, 2017. View at Publisher · View at Google Scholar · View at Scopus
  46. W. Lu, J. Wang, G. Yang et al., “Posttranscriptional regulation of galectin-3 by miR-128 contributes to colorectal cancer progression,” Oncotarget, vol. 8, no. 9, pp. 15242–15251, 2017. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Tsuboi, T. Shimura, N. Masuda et al., “Galectin-3 expression in colorectal cancer: relation to invasion and metastasis,” Anticancer Research, vol. 27, no. 4B, pp. 2289–2296, 2007. View at Google Scholar
  48. G. V. Assche, “Fecal biomarkers for the diagnosis and management of inflammatory bowel disease,” Gastroenterology & Hepatology, vol. 7, no. 6, pp. 396–398, 2011. View at Google Scholar
  49. M. Rutka, R. Bor, A. Bálint et al., “Diagnostic accuracy of five different fecal markers for the detection of precancerous and cancerous lesions of the colorectum,” Mediators of Inflammation, vol. 2016, Article ID 2492081, 6 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Krane and C. Wanner, “The metabolic burden of diabetes and dyslipidaemia in chronic kidney disease,” Nephrology, Dialysis, Transplantation, vol. 17, Supplement 11, pp. 23–27, 2002. View at Publisher · View at Google Scholar
  51. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, “Advanced glycation end products: sparking the development of diabetic vascular injury,” Circulation, vol. 114, no. 6, pp. 597–605, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Nomoto, K. Tsuneyama, H. O. Abdel Aziz et al., “Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice,” The Journal of Pathology, vol. 210, no. 4, pp. 469–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Y. Chen, A. Fermin, S. Vardhana et al., “Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 34, pp. 14496–14501, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. W. Peng, H. Y. Wang, Y. Miyahara, G. Peng, and R. F. Wang, “Tumor-associated galectin-3 modulates the function of tumor-reactive T cells,” Cancer Research, vol. 68, no. 17, pp. 7228–7236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. K. L. Wu, E. Y. Huang, E. W. Jhu et al., “Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway,” Journal of Gastroenterology, vol. 48, no. 3, pp. 350–359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Fortuna-Costa, A. M. Gomes, E. O. Kozlowski, M. P. Stelling, and M. S. G. Pavão, “Extracellular galectin-3 in tumor progression and metastasis,” Frontiers in Oncology, vol. 4, p. 138, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Cvejic, S. Savin, S. Golubovic, I. Paunovic, S. Tatic, and M. Havelka, “Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression,” Histopathology, vol. 37, no. 6, pp. 530–535, 2000. View at Publisher · View at Google Scholar · View at Scopus